News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 02 - 04

In Search of "China's Musk": A Historic Invitation

Part 01In Search of "The Musk" When Teslas cruise down the streets,When SpaceX rockets streak across the sky,We cannot help but ask ourselves:In China today,Who will become the "Musk" of the bio-economy?In recent years,China's biopharmaceutical industry has developed rapidly.The number of innovative drug pipelines currently in development is second only to the United States,Greater than the sum of Europe and Japan.In 2024, the number of new drug molecules discovered in China exceeded that of the US for the first time.According to statistics from the PharmCube NextP...

浏览次数：0

查看详情>>

发布时间: 2026 - 01 - 31

Monthly Health Digest | January 2026

Preface:In January, the "Spring Festival Gala" of the global biopharmaceutical industry – the 44th Annual J.P. Morgan Healthcare Conference – was held grandly in San Francisco, USA. Efung Capital's portfolio companies, including Ascentage Pharma, Hangzhou Gaoguang, Andao Pharma, Biao Xin Bio, and Mai Lian Ke, made major appearances, collectively showcasing the cutting-edge power of Chinese innovative drug companies.Efung's portfolio companies also achieved continuous breakthroughs in key areas such as clinical trials, regulatory approvals, and collaborations, outlining a clea...

浏览次数：0

查看详情>>

发布时间: 2026 - 01 - 19

HighLight Pharma Reports Positive Interim Phase III Results for CSU Drug TLL-018

January 18, 2026 – HighLight Pharmaceutical Co., Ltd. announced positive topline data from a pre-specified interim analysis of its Phase III clinical trial (NCT06396026, hereinafter referred to as "the study") evaluating TLL-018 (generic name: Jinoxitinib), an oral small-molecule JAK1/TYK2 inhibitor, for the treatment of Chronic Spontaneous Urticaria (CSU). The interim analysis showed that TLL-018 met the primary endpoint, demonstrating statistically significant superiority over placebo in both primary and multiple secondary efficacy endpoints, along with a favorable safety and ...

浏览次数：0

查看详情>>

发布时间: 2026 - 01 - 16

Efung Capital's Portfolio Companies Make Collective Appearance at JPM

On January 12, 2026 local time, the 44th Annual J.P. Morgan Healthcare Conference kicked off in San Francisco, USA. Efung Capital's portfolio companies – Ascentage Pharma, HighLight Pharma, Andao Pharma, NewCo Scientific, and MedLinc – made a collective appearance at JPM, with Ascentage Pharma delivering a presentation at the main forum.Efung Capital CEO Ben attended the conference, marking the firm's fourth participation in JPM. He engaged with global biotech leaders and seasoned investors to explore industry trends and partnership opportunities, while showcasing the "potential a...

浏览次数：0

查看详情>>